Sutro Biopharma, Inc. $STRO Shares Sold by AJU IB Investment Co. Ltd.

AJU IB Investment Co. Ltd. lessened its holdings in Sutro Biopharma, Inc. (NASDAQ:STRO) by 90.0% in the fourth quarter, HoldingsChannel.com reports. The firm owned 17,500 shares of the company’s stock after selling 157,500 shares during the period. Sutro Biopharma accounts for approximately 1.1% of AJU IB Investment Co. Ltd.’s investment portfolio, making the stock its 7th biggest holding. AJU IB Investment Co. Ltd.’s holdings in Sutro Biopharma were worth $202,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Jacobs Levy Equity Management Inc. acquired a new position in shares of Sutro Biopharma during the third quarter valued at $387,000. Velan Capital Investment Management LP boosted its holdings in shares of Sutro Biopharma by 2.0% during the third quarter. Velan Capital Investment Management LP now owns 3,120,000 shares of the company’s stock valued at $2,709,000 after acquiring an additional 60,000 shares during the period. Bank of America Corp DE boosted its holdings in shares of Sutro Biopharma by 51.3% during the third quarter. Bank of America Corp DE now owns 119,434 shares of the company’s stock valued at $104,000 after acquiring an additional 40,488 shares during the period. Shay Capital LLC boosted its holdings in shares of Sutro Biopharma by 20.1% during the third quarter. Shay Capital LLC now owns 312,051 shares of the company’s stock valued at $271,000 after acquiring an additional 52,162 shares during the period. Finally, Two Sigma Investments LP boosted its holdings in shares of Sutro Biopharma by 244.8% during the third quarter. Two Sigma Investments LP now owns 396,785 shares of the company’s stock valued at $345,000 after acquiring an additional 281,717 shares during the period. Institutional investors and hedge funds own 96.99% of the company’s stock.

Sutro Biopharma Stock Down 0.2%

Shares of NASDAQ STRO opened at $29.63 on Friday. Sutro Biopharma, Inc. has a fifty-two week low of $6.74 and a fifty-two week high of $43.85. The firm’s 50-day simple moving average is $30.17 and its 200 day simple moving average is $19.55. The stock has a market cap of $490.97 million, a P/E ratio of -2.68 and a beta of 1.63.

Sutro Biopharma (NASDAQ:STRO) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($2.94) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.74) by ($0.20). The company had revenue of $14.52 million for the quarter, compared to analyst estimates of $8.89 million. On average, sell-side analysts anticipate that Sutro Biopharma, Inc. will post -8.81 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on STRO shares. Wall Street Zen downgraded shares of Sutro Biopharma from a “hold” rating to a “sell” rating in a report on Saturday, May 23rd. Truist Financial raised shares of Sutro Biopharma to a “strong-buy” rating in a report on Monday, May 4th. Citizens Jmp boosted their price target on shares of Sutro Biopharma from $35.00 to $41.00 and gave the company a “market outperform” rating in a report on Thursday, April 23rd. HC Wainwright boosted their price target on shares of Sutro Biopharma from $28.00 to $50.00 and gave the company a “buy” rating in a report on Friday, May 15th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Sutro Biopharma in a report on Friday, May 8th. Three investment analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $49.11.

About Sutro Biopharma

Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.

Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.